5 Stocks to Buy as the Drug Industry Rebounds in 2023

Zacks2023-04-10

After a challenging 2022, the drug and biotech industry is showing signs of recovery in 2023. Innovation is expected to be the key to growth of the drug/biotech sector this year. The drug/biotech ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2326612652?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c23rHSrGLTeyi6ecjtGakg--~B/aD0zNDY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b","is_english":true,"pubTime":"2023-04-10 22:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2326612652","market":"us","top_or_hot":-1,"title":"5 Stocks to Buy as the Drug Industry Rebounds in 2023","media":"Zacks","content":"<div>\n<p>After a challenging 2022, the drug and biotech industry is showing signs of recovery in 2023. Innovation is expected to be the key to growth of the drug/biotech sector this year. The drug/biotech ...</p>\n\n<a href=\"https://finance.yahoo.com/news/5-stocks-buy-drug-industry-140702315.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks to Buy as the Drug Industry Rebounds in 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks to Buy as the Drug Industry Rebounds in 2023\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-10 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/5-stocks-buy-drug-industry-140702315.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a challenging 2022, the drug and biotech industry is showing signs of recovery in 2023. Innovation is expected to be the key to growth of the drug/biotech sector this year. The drug/biotech ...</p>\n\n<a href=\"https://finance.yahoo.com/news/5-stocks-buy-drug-industry-140702315.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://finance.yahoo.com/news/5-stocks-buy-drug-industry-140702315.html","article_id":"2326612652","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c23rHSrGLTeyi6ecjtGakg--~B/aD0zNDY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2326612652","pubTimestamp":1681135622,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"After a challenging 2022, the drug and biotech industry is showing signs of recovery in 2023. Innova","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"161125":"标普500","513500":"标普500ETF","BK4539":"次新股","IVV":"标普500指数ETF","CPRX":"Catalyst Pharmaceutical Partners","SSO":"两倍做多标普500ETF","FA":"First Advantage Corp.","NKTR":"内克塔治疗","BK4191":"家用电器","SPXU":"三倍做空标普500ETF","KALV":"Kalvista Pharmaceuticals Inc","BK4585":"ETF&股票定投概念","OEF":"标普100指数ETF-iShares","BK4534":"瑞士信贷持仓","TERN":"Terns Pharmaceuticals, Inc.","BK4139":"生物科技","LRMR":"Larimar Therapeutics, Inc.","BK4130":"人力资源与就业服务","BK4007":"制药","SPY":"标普500ETF","BK4535":"淡马锡持仓","BK4559":"巴菲特持仓","BK4588":"碎股","CRCT":"Cricut, Inc.","BK4550":"红杉资本持仓","SDS":"两倍做空标普500ETF","OEX":"标普100",".SPX":"S&P 500 Index","BK4581":"高盛持仓","BK4504":"桥水持仓","UPRO":"三倍做多标普500ETF","SH":"标普500反向ETF"},"translate_title":"2023年制药行业反弹时买入5只股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161125":0.6,"513500":0.6,"FA":1,"CPRX":1,"KALV":1,"NKTR":1,"LRMR":1,"JNCE":0.9,"TERN":0.67,"CRCT":0.67,"SPY":0.67,"OEF":0.6,"ESmain":0.6,"IVV":0.6,"UPRO":0.6,"OEX":0.6,"SDS":0.6,"SH":0.6,"SPXU":0.6,"SSO":0.6,".SPX":0.6},"content_text":"After a challenging 2022, the drug and biotech industry is showing signs of recovery in 2023. Innovation is expected to be the key to growth of the drug/biotech sector this year. The drug/biotech sector has been witnessing developments in pipeline areas like rare diseases, gene therapy and editing, and mRNA-based drugs and vaccines. In 2023, the sector is expected to make advances in areas like Alzheimer’s, cell and gene therapy and mRNA research.Overall, we believe that M&A, innovation, a more favorable regulatory environment and the sector’s insulation from recession concerns will shape the biotech sector in 2023, keeping stocks like Catalyst Pharmaceuticals CPRX, KalVista Pharmaceuticals KALV, Larimar Therapeutics LRMR, Nektar Therapeutics NKTR and Jounce Therapeutics JNCE afloat.\nIndustry Description\nThe Zacks Medical-Drugs industry comprises small and some medium-sized drug companies, which make medicines for both human and veterinary use. We have a separate industry outlook discussion on big drugmakers. Small drugmakers have a limited portfolio of marketed drugs or no commercial-stage drugs at all. Some drugmakers are dependent on just one marketed drug or pipeline candidate. For such companies, upfront or milestone payments from collaboration partners — in most cases their larger counterparts — are the main source of revenues. These companies need ample free cash flow to fund their R&D activities.\nFactors Shaping the Future of the Medical-Drugs Industry\nPipeline Success: The success or failure of key pipeline candidates in clinical studies can significantly drive the stock price of industry players. Successful innovation and product line extensions in important therapeutic areas and strong clinical study results may act as important catalysts for the stocks.\nStrong Collaboration Partners: These companies regularly seek external partners and collaborators for complementary strengths. A partnership deal with a popular drugmaker is a good sign about the potential of small pharma companies, especially when an equity investment is included in the deal.  M&A deals are in full swing in the sector, signaling growth. \nInvestment in Technology for Innovation: For these smaller companies, succeeding in a shifting global market and evolving healthcare landscape requires adopting innovative business models, investing in new technologies and increasing investments in personalized medicines. Over the past few years, scientific and technological advancements have made it possible to develop personalized therapies. Other than that, adoption and information exchange through the meaningful use of health IT, development of therapies that improve overall patient outcomes and investment in developing and emerging markets are some of the new priorities for drug companies.\nPipeline Setbacks: The smaller companies have their share of risk in the form of unstable cash flows. Also, the failure of key pipeline candidates in pivotal studies and regulatory and pipeline delays can be huge setbacks for these smaller companies and significantly hurt their share price in the future.\nZacks Industry Rank Indicates Bright Prospects\nThe group’s Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks.\nThe Zacks Medical-Drugs industry currently carries a Zacks Industry Rank #97, which places it in the top 39% of 250 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\nBefore we present you a few top-ranked stocks to capitalize on the thriving prospects of the small and medium-sized drugmakers’ space, let’s take a look at the industry’s recent stock-market performance and the valuation picture.\nIndustry Lags S&P 500 and Sector\nThe Zacks Medical-Drugs industry is a huge 210-stock group within the broader Medical sector. The industry has underperformed the S&P 500 and the Zacks Medical sector in the past year.\nStocks in this industry have collectively declined 17.4% in the past year, while the Zacks S&P 500 composite has declined 7.4%. The Zacks Medical sector has declined 15.9% in the said time frame.\nOne Year Price Performance\n\nIndustry's Current Valuation\nOn the basis of the trailing twelve months price-to-sales ratio (P/S TTM), which is a commonly used multiple for valuing these small drugmakers, the industry is currently trading at 1.88 compared with the S&P 500’s 3.61 and the Zacks Medical sector's 2.33.\nOver the last five years, the industry has traded as high as 4.84X, as low as 1.68X, and at the median of 2.61X, as the chart below shows.\nTrailing 12-Month Price-to-Sales (P/S) Ratio\n\n\n5 Drug Stocks to Keep an Eye On \nCatalyst Pharmaceuticals: FL-based Catalyst Pharmaceuticals’ lead drug Firdapse, approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) — an ultra-rare disease — witnessed an encouraging uptake since its launch in 2019. In 2022, Firdapse’s sales rose 52.1%. The FDA in 2022 approved the label expansion of Firdapse for treating LEMS in pediatric patients, which should further drive sales growth.\nIn January 2023, Catalyst acquired the U.S. rights for Fycompa, Eisai’s successfully marketed rare epilepsy drug. This acquisition grants Catalyst exclusive commercial rights to the drug in the United States and will provide an incremental stream of revenues. This will reduce the company’s dependency on Firdapse. \nThe stock of Catalyst Pharmaceuticals has risen 116.7% in the past year. Earnings estimates for 2023 have increased from $1.40 per share to $1.46 per share over the past 60 days. The company has a Zacks Rank #2 (Buy).\nPrice and Consensus: CPRX\n\nLarimar Therapeutics: CA-based Larimar Therapeutics is a clinical-stage company making medicines for rare diseases. Its lead pipeline candidate is CTI-1601, being developed as a potential treatment for Friedreich's ataxia (FA).  The CTI-1601 program was placed on clinical hold by the FDA in May 2021 following deaths in the high-dose arms in a pre-clinical toxicology study that was designed to support extended dosing of patients with CTI-1601. In September 2022, the FDA lifted the full clinical hold placed on the CTI-1601 program and imposed a partial hold. With the lifting of the full clinical hold, Larimar began enrollment in the first cohort (25 mg cohort) of the phase II four-week dose exploration study in FA patients. It has completed enrollment in the 25 mg cohort data with an update that will outline the next steps for study expected in the second quarter.\nPrior phase I results on CTI-1601 provided clinical proof-of-concept for the candidate by demonstrating its ability to increase frataxin levels in peripheral tissues. CTI-1601 has been granted Rare Pediatric Disease designation, Fast Track designation and Orphan Drug designations by the FDA\nThe stock of Larimar Therapeutics has risen 31.5% in the past year. The consensus estimate for 2022 loss has narrowed from $2.07 per share to $1.08 per share over the past 60 days. The company has a Zacks Rank #2.\nPrice and Consensus: LRMR\n\nNektar Therapeutics: CA-based Nektar Therapeutics, which is focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms, has a Zacks Rank #2.  You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.  \nThe consensus estimate for 2022 loss has narrowed from $1.01 per share to 90 cents per share over the past 60 days. The company has a Zacks Rank #2. The stock has declined 85.8% in the past year.\nNektar is currently focusing on the development of rezpegaldesleukin (rezpeg) and NKTR-255. While rezpeg is being developed in collaboration with Eli Lilly for several autoimmune indications, Nektar is developing NKTR-255 on its own as a cell therapy potentiator to boost the anti-tumor immune response of other cancer therapies, especially CAR T therapies.  While rezpeg is being evaluated in several mid-stage studies, NKTR-255 is in early-stage as well as mid-stage development. NKTR-255 and rezpeg represent a significant opportunity as they target indications — oncology and autoimmune, respectively — with a large patient population.\nFollowing the discontinuation of bempeg development, Nektar announced cost-restructuring plans to reduce costs and extend the cash runway. It expects its cash resources to be enough to fund its operations into the first half of 2025.\nPrice and Consensus: NKTR\n\nJounce Therapeutics: This Cambridge, MA-based clinical-stage immunotherapy company has multiple development-stage programs ongoing. Its JTX-8064 program is being evaluated in a phase I/II clinical study as a monotherapy and in combination with its own PD-1 inhibitor, pimivalimab, in patients with solid tumors. The consensus estimate for 2022 loss has narrowed from $2.25 per share to $1.71 per share over the past 60 days. The stock has declined 72% in the past year. The company has a Zacks Rank #2.\nJounce Therapeutics recently entered into an agreement to be acquired by Concentra Biosciences for $1.85 in cash per share plus a non-tradeable contingent value right. The offer price represented a premium of 75% over Jounce’s closing price immediately before Mar 14 when the proposed offer by Concerta was made public. In conjunction with the merger agreement, Jounce is implementing a workforce reduction of approximately 84% of its employees.\nFollowing the decision to merge with Concerta, Jounce Therapeutics decided to terminate the previously announced proposed all-share merger transaction with Redx Pharma.\nPrice and Consensus: JNCE\n\nKalVista Pharmaceuticals: Cambridge, MA-based KalVista Pharmaceuticals is developing sebetralstat as an oral on-demand therapy for hereditary angioedema attacks. Enrollment is ongoing in the pivotal phase III KONFIDENT study, with KalVista having already enrolled more than 50% of the targeted number of patients in the study. Data from the KONFIDENT study are expected to be reported in the second half of 2023, which, if positive, would lead KalVista to file a new drug application in the first half of 2024. In 2021, data from a phase II efficacy study showed that sebetralstat led to statistically and clinically significant responses across all primary and secondary endpoints. KalVista Pharmaceuticals recently completed a $58 million financing that will fund the company into 2025.\nThe stock of KalVista Pharmaceuticals has declined 42.6% in the past year. The consensus estimate for 2023 loss has narrowed from $3.90 per share to $3.76 per share over the past 60 days. The company has a Zacks Rank #2.\nPrice and Consensus: KALV\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCatalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report\nNektar Therapeutics (NKTR) : Free Stock Analysis Report\nKalVista Pharmaceuticals, Inc. (KALV) : Free Stock Analysis Report\nJounce Therapeutics, Inc. (JNCE) : Free Stock Analysis Report\nLarimar Therapeutics, Inc. (LRMR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2326612652"}